One Platform. Multiple applications.
Evora Pipeline
Building the Future of Diagnostic Testing
Evora Diagnostics is developing a scalable artificial intelligence-powered diagnostic platform designed to address significant unmet needs across multiple disease areas.
Our initial programs focus on conditions where earlier detection, rapid results, and improved accessibility have the potential to meaningfully improve patient outcomes.
While each program targets a unique healthcare challenge, all are built upon Evora’s core mission: delivering accurate, affordable, and accessible diagnostics to patients and healthcare providers.
OUR APPROACH
One Platform. Multiple Applications.
Evora’s diagnostic platform is designed to be adaptable across a broad range of diseases and health conditions.
By combining advanced biosensing technologies with artificial intelligence-powered analysis, we are building a flexible diagnostic architecture capable of supporting multiple testing applications while expanding access to rapid and reliable healthcare information.
Lyme Disease
Addressing a Critical Diagnostic Gap
Lyme disease is the most common vector-borne disease in the United States, affecting an estimated 476,000 Americans each year.
Despite its prevalence, Lyme disease remains difficult to diagnose, particularly during the early stages of infection when treatment is most effective. Current testing often relies on laboratory-based antibody tests that can delay answers and create uncertainty for patients.
Evora’s lead diagnostic program is focused on developing a rapid, single-tier testing solution designed to deliver faster results, improve accessibility, and support earlier clinical decision-making.
Cardiac Diagnostics
Supporting Earlier Cardiovascular Insights
Cardiovascular disease remains the leading cause of death worldwide, making rapid assessment and early intervention critically important.
Evora is developing next-generation cardiac diagnostic solutions designed to identify important cardiovascular biomarkers quickly and efficiently. By providing actionable information sooner, these technologies may help support earlier detection, risk assessment, and management of cardiovascular conditions.
Sexually Transmitted Infections
Expanding Access to Testing
Millions of sexually transmitted infections occur each year, yet barriers such as cost, accessibility, stigma, and delayed testing continue to impact diagnosis and treatment.
Evora is developing rapid diagnostic solutions designed to improve access to testing and enable earlier detection of sexually transmitted infections. By supporting testing in clinics, and pharmacies, we aim to provide greater convenience, privacy, and accessibility while helping individuals make informed healthcare decisions.
Type 1 Diabetes
SUPPORTING EARLIER DETECTION AND MONITORING
Type 1 Diabetes is a chronic autoimmune disease that affects millions of people worldwide, often developing in childhood and young adulthood. Early identification of individuals at risk can help support monitoring, clinical decision-making, and timely intervention.
Evora is exploring innovative diagnostic solutions designed to identify biomarkers associated with Type 1 Diabetes using accessible, point-of-care technologies. By combining advanced biosensing with artificial intelligence, we aim to make screening and monitoring more affordable, convenient, and accessible, helping healthcare providers and patients make informed decisions earlier in the disease journey.
Alpha-Gal Syndrome
Addressing an Emerging Health Challenge
Alpha-Gal Syndrome (AGS), often referred to as the “red meat allergy,” is an emerging tick-associated condition that can significantly impact quality of life while remaining underrecognized by many healthcare providers and patients.
As awareness continues to grow, so does the need for accessible and reliable diagnostic solutions. Evora is evaluating opportunities to improve awareness, identification, and management of Alpha-Gal Syndrome through innovative diagnostic approaches.
Peanut Allergy Testing
Improving Access to Allergy Diagnostics
Food allergies affect millions of individuals and families worldwide, with peanut allergy among the most common and potentially severe allergic conditions.
Evora is exploring rapid, affordable diagnostic solutions designed to improve accessibility and convenience for allergy testing. By providing faster diagnostic information, these technologies may help support earlier intervention, improved monitoring, and more personalized care.
FUTURE PROGRAMS
Built for Expansion
While current development efforts focus on Lyme disease and several high-priority diagnostic applications, Evora’s platform is designed to support future expansion across additional healthcare markets.
Potential areas of future exploration include:
- Infectious diseases
- Tick-borne diseases
- Chronic conditions
- Metabolic disorders
- Women’s health
- Autoimmune diseases
- Additional point-of-care diagnostic applications
As our capabilities continue to expand, we intend to pursue opportunities where rapid, accessible diagnostics can improve patient care and healthcare outcomes.
PIPELINE DISCLAIMER
Research & Development
The pipeline described above reflects Evora’s current areas of focus and ongoing research initiatives. Specific product candidates remain subject to development, validation, regulatory review, and commercialization planning.
One Platform. Endless Possibilities.
Evora Diagnostics is building a flexible diagnostic platform designed to support a new generation of faster, more accessible testing solutions across multiple disease categories.